Drug Database
BU

buprenorphine (Transtec Pro / Transtec)

✓ Approved

Napp Pharmaceuticals · OPRK1 · 小分子

什么是 buprenorphine?

buprenorphine 是一种小分子,由Napp Pharmaceuticals研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名Transtec Pro, Transtec
公司Napp Pharmaceuticals
药物类别小分子
分子靶点OPRK1, OPRM1
给药途径Topical
状态Approved

作用机制

分子靶点

buprenorphine 作用于 2 个分子靶点:

OPRK1opioid receptor kappa 1 (KOR1, OPRK)
OPRM1opioid receptor mu 1 (MOR1, LMOR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

buprenorphine 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersAbdominal pain✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Cancer pain✓ Approved

相关研究文献

PubMedHarm reduction journal2026-11-19

Multi-stakeholder perspectives on acceptability and delivery of buprenorphine for women who use drugs.

Austin Elizabeth J EJ, Violette Lauren R LR, Stewart Jenell J, Glick Sara N SN et al.

Women who use drugs (WWUD) face substantial barriers to accessing medications for opioid use disorder (MOUD), including buprenorphine. As part of a formative evaluation to co-design a community-based intervention for MOUD delivery, we explored multi-stakeholder perspectives on the acceptability and delivery of buprenorphine for WWUD. We conducted qualitative interviews with 16 WWUD (who reported lifetime history of injection drug use) and 5 healthcare and harm reduction professionals (HHRP) who work closely with WWUD. Interviews asked open-ended questions about attitudes and beliefs towards buprenorphine, experience receiving (WWUD) or facilitating receipt (HHRP) of buprenorphine, and barriers to using buprenorphine in the future. Interviews were audio-recorded, professionally-transcribed, and coded using Rapid Assessment Process. Two coders generated templated coding summaries of each transcript, which were placed into a matrix and iteratively reviewed to identify cross-cutting themes. Qualitative learnings were finalized with the investigative team and confirmed with community advisors. Among 16 WWUD participants, 12 (75%) identified as White and 11 (69%) were unstably housed. All participants had a lifetime history of injection drug use and 10 (63%) had ever tried buprenorphine. Most WWUD did not perceive buprenorphine to be the right choice for them, in part due to beliefs about its limited effectiveness and concerns about their personal safety and stigmatizing beliefs. Fear of physical discomfort from buprenorphine inductions further discouraged willingness, especially for those using fentanyl. Participants described the ways in which housing instability and limited social supports compounded barriers to starting and staying on buprenorphine, but that harm reduction approaches might help. WWUD face multilevel barriers to buprenorphine use and both WWUD and HHRP are working to respond to the ways in which fentanyl further heightens those barriers. Future efforts to expand buprenorphine use among WWUD should consider supports that improve the ease and acceptability of buprenorphine delivery.

PMID 43053082
阅读全文 →
PubMedJournal of pain and symptom management2026-11-18

Divergent Mechanisms of Reward Reduction in Buprenorphine and Methadone: Implications for Opioid Selection in Cancer Pain with Elevated Misuse Liability.

Davis Mellar P MP

Buprenorphine and methadone both reduce opioid reward, but by distinct mechanisms: buprenorphine competitively blunts a co-administered full agonist's reward, whereas methadone's reduced reward is a receptor-selective property of methadone itself, not a blocking action transferable to a second agonist.

PMID 43051325
阅读全文 →
PubMedDrug and alcohol dependence2026-11-18

Higher county-level need is associated with greater naloxone distribution from U.S. syringe services programs in 2023: A cross-sectional study.

Lambdin Barrot H BH, Humphrey Jamie J, Saunders McKinley M, Wenger Lynn L et al.

To assess whether U.S. syringe services programs (SSPs) in counties with higher levels of need in 2022 had greater financial resources and larger-scale delivery of overdose prevention interventions in 2023. This study utilized a cross-sectional design. As a measure of underlying, community-level need, our primary exposure was 2022 county-level opioid overdose fatalities, categorized as low (1-33), moderate (34-198), or high (199-1923). Outcomes included annual SSP budget, number of naloxone recipients from the SSP, naloxone doses distributed by the SSP, and buprenorphine availability at the SSP. Using weighted generalized estimating equations with exchangeable correlation structures to account for clustering of SSPs within Census divisions, we used gamma, negative binomial, and logit specifications as appropriate for each outcome. SSPs reported a median budget of $141,842; 596 naloxone recipients; 2001 naloxone doses distributed; and 44% had integrated buprenorphine. Compared to SSPs in low overdose fatality counties, SSPs in moderate- and high overdose fatality counties had significantly larger budgets, greater number of naloxone recipients and greater number of naloxone doses distributed. SSPs in higher need counties were not significantly more likely to have buprenorphine available (aOR=1.40; 95% CI:0.72-2.75; p = 0.321). Our findings showed that higher levels of need were positively associated with greater financial resources for and naloxone distribution from SSPs in 2023 but was not associated with greater buprenorphine availability. Aligning higher levels of naloxone distribution with higher need maximizes potential for population health impact. Focused infrastructure and implementation support for buprenorphine integration at SSPs likely remain.

PMID 43050840
阅读全文 →
PubMedAmerican journal of veterinary research2026-11-17

Multiple-dose oral metoclopramide does not increase food intake or fecal output in healthy New Zealand white rabbits (Oryctolagus cuniculus) with experimentally induced hyporexia.

Stratton Hayley S HS, Ozawa Sarah M SM, Serrano Maria M, Hertzig Isabella I et al.

To evaluate the effects of multiple-dose oral metoclopramide administration on food intake, fecal output, and body weight in healthy rabbits with experimentally induced hyporexia. Two pilot studies were performed to inform the methods of the main study. In the main study, twelve 3-month-old intact (6 male and 6 females; body weight, 2.6 ± 0.17 kg) New Zealand white rabbits (Oryctolagus cuniculus) were used in a randomized, blinded, placebo-controlled complete crossover study. Hyporexia was successfully induced in 11 of 12 rabbits by administering high-concentration buprenorphine (0.24 mg/kg) SC every 24 hours for 2 days. Following induction of hyporexia, rabbits (n = 11) were administered metoclopramide (5 mg/kg) orally every 12 hours for 2 days based upon pilot study results. Fecal output, food intake, and body weight were measured daily before, during, and after treatment to assess the effects of metoclopramide on these parameters. Administration of high-concentration buprenorphine produced a significant decrease in food intake and fecal output compared to baseline in both the metoclopramide and control treatments. There was no significant difference in food intake or fecal output over time between the metoclopramide and control treatments. Oral administration of metoclopramide at 5 mg/kg every 12 hours for 2 days had no clinically relevant or statistically significant effect on food intake or fecal output in healthy rabbits with experimentally induced hyporexia. Current knowledge regarding the efficacy of metoclopramide in hyporexic rabbits does not support its routine use in clinical situations.

PMID 43044228
阅读全文 →
PubMedJMIR research protocols2026-11-17

A Comprehensive Intervention to Enhance Treatment Engagement and Retention Following Nonfatal Opioid Overdose: Protocol for a Single-Arm Prospective Feasibility Study.

Chaparala Rohit R, McPherson Gray G, Walter Lauren A LA, Malhotra Aniket A et al.

Substance use treatment engagement and retention after hospital discharge remain low among patients with nonfatal opioid overdose. It is critical to develop interventions targeting this population due to the persistent opioid overdose crisis. We conducted a single-arm prospective study, the first phase of a 2-phase study (R61/R33, funded by the National Institute on Drug Abuse; DA062351). The objective of the R61 phase was to evaluate the feasibility and acceptability of a 12-week bundled telehealth-enabled intervention aimed at improving treatment engagement and retention among patients with opioid use disorder and a recent nonfatal opioid overdose after hospital discharge. The R61 phase was a single-arm study with no control group. The 12-week comprehensive intervention comprised 4 components, including buprenorphine treatment, telehealth physician visits (weeks 1, 3, 5, 9, and 12 and as needed), telehealth peer service (daily during week 1, every other day during week 2, weekly during weeks 3-12, and as needed), and facilitated linkage to community resources and ongoing treatment. Adults aged 19 years or older with a diagnosis of opioid use disorder and a nonfatal opioid overdose within the previous 12 months were recruited before they were discharged from the University of Alabama at Birmingham Hospital. After enrollment, buprenorphine treatment was initiated or continued, and peer support specialists began engaging and coaching patients. Participants completed validated surveys at baseline and 1 and 3 months. Feasibility will be measured using enrollment and retention rates (benchmark of ≥70% at 3 months). Acceptability will be measured using patient satisfaction and credibility and expectancy scores. Mental health, craving, repeat overdose, and emergency department revisits and readmissions are secondary outcomes. Outcomes will be summarized descriptively. The R61 study was funded by the National Institute on Drug Abuse from October 1, 2024, to August 30, 2026. All 30 anticipated participants were enrolled, and 24 completed the intervention. The last participant completed the intervention in April 2026. Data analysis is currently ongoing, and results from the current study are expected to be published in January 2027. Funding for the subsequent R33 phase was awarded in September 2026. This study evaluated the feasibility and acceptability of a bundled telehealth-enabled intervention for patients at high risk of repeat overdose and death, a patient population with low treatment uptake and retention after hospital discharge. The findings will inform the upcoming R33 phase, a randomized controlled trial aiming to demonstrate effectiveness in an estimated sample of 160 patients. DERR1-10.2196/109601.

PMID 43044112
阅读全文 →
PubMedThe Annals of pharmacotherapy2026-11-16

Individualized Tapering of Long-term High-Dose Intramuscular Meperidine With Intermittent Low-Dose Buprenorphine in an Older Adult.

Wang Hui H

PMID 43036872
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多buprenorphine